Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader-Reference-Cited by-同舟云学术

Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader

Published:2019-08-28 Issue:9 Volume:14 Page:2024-2034
ISSN:1554-8929
Container-title:ACS Chemical Biology
language:en
Short-container-title:ACS Chem. Biol.

Author:

Tovell Hannah¹^ORCID,Testa Andrea²^ORCID,Zhou Houjiang¹,Shpiro Natalia¹,Crafter Claire³,Ciulli Alessio²^ORCID,Alessi Dario R.¹^ORCID

Affiliation:

1. Medical Research Council (MRC) Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, United Kingdom

2. Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dow Street, Dundee, DD1 5EH, United Kingdom

3. Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom

Funder

AstraZeneca

Medical Research Council

GlaxoSmithKline

FP7 Ideas: European Research Council

Merck

Boehringer Ingelheim

Biotechnology and Biological Sciences Research Council

Publisher

American Chemical Society (ACS)

Subject

Molecular Medicine,General Medicine,Biochemistry

Link

http://pubs.acs.org/doi/pdf/10.1021/acschembio.9b00505

Reference48 articles.

1. PI3K signalling: the path to discovery and understanding

2. Targeting PI3 Kinase/AKT/mTOR Signaling in Cancer

3. Activation of serum- and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2

4. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)

5. AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stereochemical inversion at a 1,4-cyclohexyl PROTAC linker fine-tunes conformation and binding affinity;Bioorganic & Medicinal Chemistry Letters;2024-09

2. Targeted protein degradation: current molecular targets, localization, and strategies;Drug Discovery Today;2024-09

3. Selective Degradation of MLK3 by a Novel CEP1347-VHL-02 PROTAC Compound Limits the Oncogenic Potential of TNBC;Journal of Medicinal Chemistry;2024-08-29

4. Structure-Based Design of CBP/EP300 Degraders: When Cooperativity Overcomes Affinity;JACS Au;2024-08-08

5. Precision oncology revolution: CRISPR-Cas9 and PROTAC technologies unleashed;Frontiers in Genetics;2024-07-31